Hematology Practice Questions

Q: Which of the following statements is true regarding oral therapy for iron deficiency anemia?

Absorption of iron decreases as symptoms improve.. The correct answer is **D: Absorption of iron decreases as symptoms improve.** **1. Why Option D is Correct:** Iron absorption is a tightly regulated physiological process. In iron deficiency anemia (IDA), the body’s iron stores are depleted, leading to a downregulation of **hepcidin** (the master regulator of iron). Low hepcidin levels allow for maximal absorption of iron through the ferroportin channels in the duodenum [1]. As oral therapy progresses and hemoglobin levels/iron stores normalize, hepcidin levels rise, which subsequently inhibits ferroportin and **decreases the efficiency of iron absorption** [3]. **2. Why the Other Options are Incorrect:** * **Option A:** In a state of iron deficiency, only about **10–20% (approx. 30–60 mg)** of a 300 mg dose of elemental iron is absorbed. The body cannot absorb 100 mg from a single dose due to the mucosal block and limited transport capacity [2]. * **Option B:** Reticulocytosis begins within 3–5 days, but it **peaks much earlier**, typically between **7 to 10 days**. It does not take 3–4 weeks to peak. * **Option C:** A response to therapy (indicated by a rise in hemoglobin) is seen much sooner. Hemoglobin typically begins to rise within **1 to 2 weeks**, and a significant increase (usually >2 g/dL) is expected by 3–4 weeks. **3. NEET-PG High-Yield Pearls:** * **Best Absorption:** Iron is best absorbed in the **ferrous (Fe2+) state** in an acidic environment (often prescribed with Vitamin C/Orange juice) [2]. * **Dose:** The standard therapeutic dose for IDA is **100–200 mg of elemental iron** daily. * **Duration:** Therapy must continue for **3–6 months** after hemoglobin normalizes to replenish bone marrow iron stores (monitored via Serum Ferritin). * **Side Effects:** Gastrointestinal upset (nausea, constipation, metallic taste) is the most common reason for non-compliance.

Q: A patient with rheumatic heart disease, mitral stenosis, and atrial fibrillation is on oral warfarin. On an OPD visit, his INR is found to be 6. What is the recommended action?

Stop warfarin, and review. **Explanation:** The management of supratherapeutic INR in patients on Warfarin is a high-yield topic governed by the **ACCP (American College of Chest Physicians) guidelines**. The primary factors determining management are the **INR value** and the **presence or absence of bleeding.** **1. Why Option A is Correct:** In this scenario, the patient has an INR of 6.0 but is **asymptomatic** (no mention of bleeding). According to guidelines, for patients with an **INR between 4.5 and 10.0 and NO clinically significant bleeding**, the recommended action is to **omit the next few doses of Warfarin** and monitor (review) the INR frequently [1]. Warfarin can be resumed at a lower dose once the INR returns to the therapeutic range. **2. Why Other Options are Incorrect:** * **Option B (FFP):** Fresh Frozen Plasma (or Prothrombin Complex Concentrate) is reserved for patients with **major or life-threatening bleeding**, regardless of the INR level. It is not indicated for asymptomatic elevation. * **Option C (Oral Vitamin K):** Oral Vitamin K (1–2.5 mg) is generally reserved for asymptomatic patients with an **INR > 10.0**. At an INR of 6.0 without bleeding, it is not routinely required. * **Option D (IM Vitamin K):** Intramuscular administration of Vitamin K should be **avoided** in patients on anticoagulants due to the high risk of hematoma formation at the injection site. **Clinical Pearls for NEET-PG:** * **INR 10.0 (No bleeding):** Hold Warfarin and give **Oral Vitamin K** (2.5–5 mg). * **Any INR with Serious/Life-threatening Bleeding:** Hold Warfarin + **IV Vitamin K** (10 mg) + **4-factor PCC** (preferred) or **FFP**. * **Target INR for Mitral Stenosis with AF:** 2.0 – 3.0 [2].

Q: Which of the following is a major criterion for the diagnosis of polycythemia vera?

Presence of JAK-2 mutation. Polycythemia Vera (PV) is a chronic myeloproliferative neoplasm characterized by the autonomous overproduction of red blood cells. The diagnosis is based on the **WHO 2016/Revised 4th Edition criteria**, which divides findings into Major and Minor categories. **1. Why Option A is Correct:** The **presence of a JAK2 mutation** (specifically *JAK2V617F* in ~95% of cases or *JAK2* exon 12 mutation in ~5%) is a **Major Criterion** [1]. This mutation leads to constitutive activation of the JAK-STAT signaling pathway, making erythroid progenitors hypersensitive to erythropoietin (EPO) and driving erythropoiesis independent of physiological control. **2. Analysis of Incorrect Options:** * **Option B (Low EPO levels):** While characteristic of PV, a subnormal serum EPO level is classified as a **Minor Criterion**, not a major one. It helps differentiate primary polycythemia (low EPO) from secondary causes like hypoxia (high EPO). * **Option C (High LAP score):** An elevated LAP score is often seen in PV, but it is a non-specific finding and is **not part of the formal WHO diagnostic criteria**. * **Option D (Thrombocytosis):** While PV is a panmyelosis (increase in all cell lines), thrombocytosis is a common clinical feature but **not a diagnostic criterion**. **3. NEET-PG High-Yield Pearls:** * **WHO Major Criteria for PV:** 1. Hemoglobin >16.5 g/dL (men) / >16.0 g/dL (women) OR Hematocrit >49% (men) / >48% (women) [1]. 2. Bone marrow biopsy showing hypercellularity for age with trilineage growth (panmyelosis) [1]. 3. Presence of *JAK2V617F* or *JAK2* exon 12 mutation [1]. * **Clinical Presentation:** Patients often present with **aquagenic pruritus** (itching after a hot bath), facial plethora, and splenomegaly [1]. * **Complications:** Increased risk of thrombotic events (Budd-Chiari syndrome) and transformation to myelofibrosis or AML [1].

Q: For which procedure is the following instrument used?

Bone marrow examination. ***Bone marrow examination*** - The instrument shown is a **Jamshidi needle** (bone marrow biopsy needle) with characteristic **trocar tip**, **outer cannula with stylet**, and **T-shaped handle** for optimal grip and control. - Specifically designed for **bone marrow aspiration** and **core biopsy** from sites like **posterior iliac crest**, allowing collection of both liquid marrow and solid tissue samples. *Liver biopsy* - Liver biopsies use **Menghini needles** or **Tru-cut needles** which are thinner, shorter, and lack the robust construction needed for penetrating bone. - These needles have **different tip designs** (cutting or suction) optimized for soft tissue sampling, not the thick cortical bone overlying marrow. *Pleural biopsy* - Pleural biopsies utilize **Abrams needles** or **Cope needles** which have **hooked or notched tips** specifically designed to scrape pleural tissue. - These instruments are **smaller gauge** and designed for accessing the **pleural space**, not for penetrating dense bone tissue. *Lumbar puncture* - Lumbar puncture uses **Quincke spinal needles** or **Whitacre needles** which are much **thinner (22-25 gauge)** and **longer** for reaching the subarachnoid space. - These needles have **pencil-point or cutting tips** designed for **CSF aspiration** only, without the robust construction needed for bone penetration.

Q: A 28-year-old man presents with a new onset rash on both legs for 1 week. He has no past medical history and is not taking any medications. He denies recent fever but reports occasional gum bleeding and one episode of epistaxis 4 days ago. He is a non-smoker, drinks alcohol socially, and denies recreational drug use. Physical examination reveals no lymphadenopathy or hepatosplenomegaly. Laboratory studies show hemoglobin 14.8 gm/dL, hematocrit 42%, MCV 86 fL, leukocyte count 6,000/mL, and platelet count 22,000/mL. Liver and renal function tests are normal. Peripheral smear shows decreased platelet count with no red cell abnormalities. What is the most probable diagnosis?

Immune thrombocytopenic purpura. **Explanation:** The patient presents with **isolated thrombocytopenia** (platelets 22,000/mL) in the absence of anemia, leukopenia, or systemic symptoms like fever, lymphadenopathy, or hepatosplenomegaly. This clinical picture is classic for **Immune Thrombocytopenic Purpura (ITP)**. **Why ITP is the correct answer:** ITP is an acquired autoimmune disorder characterized by the immune-mediated destruction of platelets [1]. In adults, it often presents as a diagnosis of exclusion. Key diagnostic features seen here include: * **Isolated thrombocytopenia:** Normal Hb and WBC counts. * **Normal peripheral smear:** No schistocytes (ruling out TTP/HUS) or blasts (ruling out leukemia). * **Clinical presentation:** Mucocutaneous bleeding (epistaxis, gum bleeding) and petechiae/purpura (the "rash" on the legs) without systemic illness [2], [3]. **Why the other options are incorrect:** * **Acute Lymphoblastic Leukemia (ALL):** Typically presents with "B-symptoms" (fever, weight loss), lymphadenopathy, hepatosplenomegaly, and significant abnormalities in other cell lines (anemia, high/low WBC) with blasts on the smear. * **Leukemoid Reaction:** This is an exaggerated WBC response (>50,000/mL) to infection or stress. This patient has a normal leukocyte count (6,000/mL). * **Chronic Lymphocytic Leukemia (CLL):** Usually seen in older adults (>60 years) and presents with significant lymphocytosis and lymphadenopathy. **High-Yield Pearls for NEET-PG:** * **ITP Treatment:** Start steroids if platelets <30,000/mL or if significant bleeding occurs. IVIG is used for rapid platelet elevation. * **Bone Marrow:** In ITP, bone marrow shows **increased megakaryocytes** (compensatory response). * **Secondary ITP:** Always screen for underlying HIV, Hepatitis C, or SLE in adults diagnosed with ITP [1].

Q: What is the first-line treatment for the T315I mutation in Chronic Myeloid Leukemia (CML) management?

Ponatinib. **Explanation:** Chronic Myeloid Leukemia (CML) is characterized by the BCR-ABL1 fusion gene [2]. While first and second-generation Tyrosine Kinase Inhibitors (TKIs) are effective, resistance often develops due to mutations in the ABL kinase domain [1]. **1. Why Ponatinib is correct:** The **T315I mutation** (often called the "gatekeeper mutation") involves a substitution of threonine with isoleucine at position 315. This change creates a bulky side chain that sterically hinders the binding of most TKIs. **Ponatinib** is a third-generation TKI specifically designed with a carbon-carbon triple bond ethynyl linkage that bypasses this steric hindrance, making it the **first-line and only standard TKI effective against the T315I mutation.** **2. Why other options are incorrect:** * **Bosutinib (Option A):** A second-generation TKI. While effective against many mutations, it is ineffective against T315I. * **Tofacitinib (Option B):** This is a JAK inhibitor used in rheumatoid arthritis and ulcerative colitis; it has no role in BCR-ABL1 inhibition. * **Nilotinib (Option D):** A second-generation TKI. Like Imatinib and Dasatinib, it cannot bind to the ABL kinase domain when the T315I mutation is present [2]. **Clinical Pearls for NEET-PG:** * **Asciminib:** A newer "STAMP" inhibitor (Specifically Targeting the ABL Myristoyl Pocket) is also effective against T315I and is used in resistant cases. * **Side Effect Alert:** Ponatinib is associated with a high risk of **arterial occlusive events** (thrombosis) and hypertension; patients must be monitored for cardiovascular complications. * **Imatinib:** Still the first-line treatment for standard (non-mutated) chronic phase CML [2].

Q: What is the most common site of lymph node enlargement in Hodgkin's lymphoma?

Mediastinal. **Explanation:** In **Hodgkin’s Lymphoma (HL)**, the disease typically originates in a single node or chain of nodes and spreads predictably to anatomically contiguous groups. **Why Mediastinal is the Correct Answer:** While cervical lymphadenopathy is the most common *palpable* presentation (found in 60-80% of patients during physical examination), **mediastinal involvement** is the most common site of lymph node enlargement overall when considering both clinical and radiological findings. Approximately **60% to 80% of patients** with the Nodular Sclerosis subtype (the most common variant) present with a mediastinal mass. In modern clinical practice and imaging-based staging, the mediastinum is recognized as the most frequently involved site. **Analysis of Incorrect Options:** * **A. Cervical:** This is the most common site for *peripheral* or *palpable* lymphadenopathy. If the question specifically asks for the most common "palpable" site, cervical is the answer. However, in a general context, mediastinal involvement is more frequent. * **B. Axillary:** Involved in about 10-20% of cases; it is rarely the primary or most common site. * **C. Abdominal:** Para-aortic and splenic involvement occur but are less common than supradiaphragmatic sites (Cervical/Mediastinal). Abdominal involvement is more characteristic of Non-Hodgkin Lymphoma (NHL). **High-Yield Clinical Pearls for NEET-PG:** * **Bimodal Age Distribution:** HL peaks in the 20s and again after age 50. * **Reed-Sternberg (RS) Cells:** The diagnostic hallmark (classic "Owl’s eye" appearance). * **Nodular Sclerosis:** The most common histological subtype; frequently presents with a large mediastinal mass in young females. * **Spread:** HL spreads in a **contiguous** fashion (node to adjacent node), unlike NHL which is often disseminated. * **Alcohol-induced pain:** A rare but classic symptom where lymph nodes become painful after alcohol consumption.

Q: Neurological symptoms and premature graying of hair are associated with which of the following conditions?

Pernicious anemia. **Explanation:** The correct answer is **Pernicious Anemia (Option B)**. This condition is an autoimmune disorder characterized by the destruction of gastric parietal cells, leading to a deficiency of **Intrinsic Factor (IF)**. Since IF is essential for the absorption of Vitamin B12 in the terminal ileum, its absence results in Vitamin B12 deficiency [1]. **Why Pernicious Anemia is correct:** 1. **Neurological Symptoms:** Vitamin B12 is crucial for myelin synthesis. Deficiency leads to **Subacute Combined Degeneration (SCD)** of the spinal cord, involving the posterior and lateral columns. Symptoms include loss of vibration/position sense, paresthesia, and ataxia. 2. **Premature Graying of Hair:** Vitamin B12 deficiency is a well-documented cause of reversible premature graying (canities) and skin hyperpigmentation. **Analysis of Incorrect Options:** * **Option A (Folic acid deficiency):** While it causes megaloblastic anemia similar to B12 deficiency, it **does not** cause neurological symptoms or premature graying. * **Options C & D (Plummer-Vinson / Paterson-Kelly syndrome):** These are synonyms for the same condition characterized by the triad of **Iron Deficiency Anemia, esophageal webs, and dysphagia**. It is associated with glossitis and koilonychia, but not neurological deficits or graying hair. **High-Yield Clinical Pearls for NEET-PG:** * **Schilling Test:** Historically used to diagnose Pernicious Anemia (now largely replaced by Anti-Intrinsic Factor and Anti-Parietal cell antibody titers). * **MCV:** Typically >100 fL (Megaloblastic). * **Peripheral Smear:** Shows hypersegmented neutrophils (earliest sign) and macro-ovalocytes. * **Metabolic Markers:** Both **Methylmalonic acid (MMA)** and **Homocysteine** levels are elevated in B12 deficiency (only Homocysteine is elevated in Folate deficiency).

Question 1

Which of the following statements is true regarding oral therapy for iron deficiency anemia?

Accepted Answer

Absorption of iron decreases as symptoms improve.

Answer

Approximately 100 mg of elemental iron is absorbed from a 300 mg dose.

Answer

Reticulocytosis appears within one to two weeks and peaks in three to four weeks.

Answer

A response to therapy is typically seen within four weeks.

Question 2

All of the following statements about hereditary hemochromatosis are true EXCEPT?

Accepted Answer

Desferroxamine is the treatment of choice

Answer

Arthropathy involving small joints of hands may be seen

Answer

Skin pigmentation is a frequent presentation

Answer

Hypogonadism may be seen

Question 3

A patient with rheumatic heart disease, mitral stenosis, and atrial fibrillation is on oral warfarin. On an OPD visit, his INR is found to be 6. What is the recommended action?

Accepted Answer

Stop warfarin, and review

Answer

Stop warfarin, and administer fresh frozen plasma

Answer

Stop warfarin, and administer oral vitamin K

Answer

Stop warfarin, and administer intramuscular vitamin K

Question 4

Which of the following is a major criterion for the diagnosis of polycythemia vera?

Accepted Answer

Presence of JAK-2 mutation

Answer

Low erythropoietin levels

Answer

High leukocyte alkaline phosphatase (LAP) score

Answer

Thrombocytosis

Question 5

For which procedure is the following instrument used?

Accepted Answer

Bone marrow examination

Answer

Liver biopsy

Answer

Pleural biopsy

Answer

Lumbar puncture

Question 6

Which of the following is absent in hemolytic anemia?

Accepted Answer

Increased direct bilirubin

Answer

Increased indirect bilirubin

Answer

Increased reticulocyte count

Answer

Jaundice

Question 7

A 28-year-old man presents with a new onset rash on both legs for 1 week. He has no past medical history and is not taking any medications. He denies recent fever but reports occasional gum bleeding and one episode of epistaxis 4 days ago. He is a non-smoker, drinks alcohol socially, and denies recreational drug use. Physical examination reveals no lymphadenopathy or hepatosplenomegaly. Laboratory studies show hemoglobin 14.8 gm/dL, hematocrit 42%, MCV 86 fL, leukocyte count 6,000/mL, and platelet count 22,000/mL. Liver and renal function tests are normal. Peripheral smear shows decreased platelet count with no red cell abnormalities. What is the most probable diagnosis?

Accepted Answer

Immune thrombocytopenic purpura

Answer

Acute lymphoblastic leukemia

Answer

Leukemoid reaction

Answer

Chronic lymphocytic leukemia

Question 8

What is the first-line treatment for the T315I mutation in Chronic Myeloid Leukemia (CML) management?

Accepted Answer

Ponatinib

Answer

Bosutinib

Answer

Tofacitinib

Answer

Nilotinib

Question 9

What is the most common site of lymph node enlargement in Hodgkin's lymphoma?

Accepted Answer

Mediastinal

Answer

Cervical

Answer

Axillary

Answer

Abdominal

Question 10

Neurological symptoms and premature graying of hair are associated with which of the following conditions?

Accepted Answer

Pernicious anemia

Answer

Folic acid deficiency

Answer

Plummer-Vinson syndrome

Answer

Paterson-Kelly syndrome

Hematology — MCQs

Hematology — MCQs

On this page

Practice by Chapter

Want unlimited practice?